No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
219 |
4. Check minimum number of eventsNone |
219 |
5. Include endpointsNone |
219 |
6. Filter based on genotype QC (FinnGen only) |
213 |
Control definitions (FinnGen only)
- Control exclude
- RHEUMA_CHRYSTAL
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other/unspecified crystal arthropathies
based on the number of shared cases.
Similar with more cases:
- Other crystal arthropathies
- Crystal arthropathies, rheuma endpoint
- Polyarthropathies
- Finngen Rheumatological endpoints
- Arthropathies
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1547 | 864 | 670 |
| Only index persons | 1294 | 716 | 578 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 73.60 | 75.80 | 70.78 |
| Only index persons | 72.74 | 74.85 | 70.12 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 213 | 114 | 99 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.05 |
| Median age at first event (years) | 71.08 | 70.95 | 71.23 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 219
- Matched controls
- 2190
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M11.9
ICD-10 Finland
Crystal arthropathy, unspecified
+∞
126.7
109
*
M11.8
ICD-10 Finland
Other specified crystal arthropathies
2098.8
123.4
108
*
M13.9
ICD-10 Finland
Arthritis, unspecified
15.3
76.6
81
81
M10.9
ICD-10 Finland
Gout, unspecified
6.9
28.1
50
90
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
7.6
27.7
44
70
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
5.0
24.2
65
170
M11.2
ICD-10 Finland
Other chondrocalcinosis
140.4
24.1
25
*
H02AB06
ATC
prednisolone; systemic
3.9
20.2
151
794
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
6.6
19.5
34
59
N02AX02
ATC
tramadol; systemic, rectal
3.6
18.9
140
721
M00.9
ICD-10 Finland
Pyogenic arthritis, unspecified
29.7
18.2
24
9
M17.1
ICD-10 Finland
Other primary gonarthrosis
3.4
17.3
92
381
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.1
16.9
56
169
M17.9
ICD-10 Finland
Gonarthrosis, unspecified
3.7
14.4
55
182
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
5.2
13.0
29
63
L15
ICPC
Knee symptom/complaint
3.0
12.2
76
334
X59
ICD-10 Finland
Exposure to unspecified factor
3.1
12.1
63
250
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.8
12.1
140
848
M79.6
ICD-10 Finland
Pain in limb
2.7
12.0
118
657
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.5
12.0
47
157
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
4.0
11.9
38
110
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
4.8
11.9
29
68
M17.0
ICD-10 Finland
Primary gonarthrosis, bilateral
3.1
11.6
62
250
A46
ICD-10 Finland
Erysipelas
3.1
11.2
58
229
SPAT1211
SPAT
Application of soft bandage
3.8
10.5
36
109
N03AX16
ATC
[U] pregabalin
2.7
10.5
73
337
T84.0
ICD-10 Finland
Mechanical complication of internal joint prosthesis
5.3
10.5
22
45
NGB40
NOMESCO Finland
Primary total prosthetic replacement of knee joint with patellar part - sliding prosthesis
5.4
10.3
21
42
NF1AA
NOMESCO Finland
Hip X-ray examination
3.5
10.2
40
133
J01FF01
ATC
clindamycin; systemic
2.6
10.1
82
409
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.9
9.9
59
250
UKC02
NOMESCO Finland
Cystoscopy
2.8
9.5
59
255
J01DB01
ATC
cefalexin; oral
3.6
9.3
193
1479
TPH04
NOMESCO Finland
Cathetrisation of vein
2.6
9.1
67
316
L28
ICPC
Limited function/disability (L)
2.6
9.1
66
309
AA1AD
NOMESCO Finland
CT of head and brain
2.4
8.8
86
462
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
3.6
8.7
31
96
N02AJ06
ATC
codeine and paracetamol; systemic
2.3
8.7
109
651
M25.5
ICD-10 Finland
Pain in joint
2.4
8.6
84
451
M19.0
ICD-10 Finland
Primary arthrosis of other joints
3.1
8.5
40
148
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.8
8.4
51
217
C03CA01
ATC
furosemide; systemic
2.3
8.4
109
660
N19
ICD-10 Finland
Unspecified kidney failure
4.7
8.3
20
46
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.0
8.0
40
153
NGB20
NOMESCO Finland
Primary total prosthetic replacement of knee joint without patellar part
2.9
7.9
43
172
L04AX03
ATC
methotrexate; systemic
3.2
7.8
33
114
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.4
7.8
65
322
NGC00
NOMESCO Finland
Exchange of a loose part of prosthesis in knee joint
46.7
7.8
9
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
3.6
7.7
26
78
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
2.9
7.6
40
157
M10.0
ICD-10 Finland
Idiopathic gout
4.7
7.6
18
41
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
3.3
7.4
30
101
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.5
7.4
53
244
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
2.7
7.2
43
181
M15.9
ICD-10 Finland
Polyarthrosis, unspecified
3.2
7.0
29
99
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.2
7.0
83
476
P01BA02
ATC
hydroxychloroquine; oral
3.1
6.9
31
111
R50.9
ICD-10 Finland
Fever, unspecified
2.6
6.9
44
191
T84.5
ICD-10 Finland
Infection and inflammatory reaction due to internal joint prosthesis
9.8
6.9
13
14
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.7
6.9
41
172
M04AA01
ATC
allopurinol; systemic
2.5
6.8
48
219
JN4AD
NOMESCO Finland
Body CT examination
3.0
6.8
33
124
L90
ICPC
Osteoarthrosis of knee
3.3
6.8
27
90
M54.9
ICD-10 Finland
Dorsalgia, unspecified
2.8
6.7
37
149
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.4
6.7
54
262
A02BC02
ATC
pantoprazole; systemic
2.3
6.7
163
1227
I50.9
ICD-10 Finland
Heart failure, unspecified
2.3
6.5
59
301
M35.3
ICD-10 Finland
Polymyalgia rheumatica
3.5
6.5
23
71
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
8.1
6.2
13
17
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.4
6.2
51
249
M03BX02
ATC
tizanidine; oral
2.1
6.2
132
931
R60.0
ICD-10 Finland
Localized oedema
2.5
6.1
41
182
M48.0
ICD-10 Finland
Spinal stenosis
2.5
6.1
45
209
NG1AE
NOMESCO Finland
Knee joint ultrasound exmination
10.5
6.1
11
11
J01MA12
ATC
levofloxacin; systemic
2.2
6.1
61
324
M09AX01
ATC
hyaluronic acid; parenteral
3.2
6.0
24
80
S18
ICPC
Laceration/cut
2.0
6.0
118
805
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
93
49
32.25
126.03
1.9
1.2
—
—
—
0
0
64
42
21.12
76.60
2.3
1.5
31963.07
33394.67
e6/l
0.02
44
27
44
51
10.55
36.20
1.9
1.5
—
—
—
0
0
135
492
5.55
35.22
3.8
2.6
334.68
5271.83
umol/l
1.77
119
413
84
258
4.66
25.72
1.5
1.3
4.75
10.89
u/ml
0.64
32
99
81
277
4.05
20.91
1.5
1.3
17.43
32.80
iu/ml
1.58
23
90
28
38
8.30
19.99
2.0
1.6
—
—
—
0
0
78
278
3.80
18.70
3.3
2.3
19.76
21.86
%
0.77
69
234
54
151
4.42
18.08
5.1
3.4
98.65
82.65
ng/l
0.46
43
130
26
15
19.48
17.42
1.5
1.0
68717.65
617861.11
e6/l
—
17
9
80
321
3.35
15.58
3.5
2.3
10.47
12.43
umol/l
2.12
75
289
160
987
3.31
14.34
11.1
5.9
1.22
1.22
mmol/l
0.33
135
834
75
314
3.11
13.32
2.5
1.8
—
—
—
0
0
49
158
3.71
13.21
2.9
3.0
67.16
66.60
g/l
0.20
43
142
149
910
2.99
13.05
9.7
5.2
1.22
1.21
mmol/l
0.24
138
826
98
489
2.82
12.50
2.8
2.1
3.61
3.23
mg/l
0.37
82
419
38
111
3.93
11.74
1.5
1.3
—
—
—
0
0
55
213
3.11
10.96
2.1
1.7
—
—
—
0
0
29
74
4.36
10.69
1.8
2.1
—
—
—
0
0
180
1301
3.15
10.19
7.9
4.3
22.30
13.90
mm/h
6.16
170
1189
121
726
2.49
9.97
3.9
2.6
150.28
132.19
ug/l
0.59
108
648
35
109
3.63
9.81
2.0
1.5
—
—
—
0
0
153
1029
2.62
9.77
12.3
8.5
4.68
4.20
e9/l
1.40
133
902
146
962
2.55
9.71
23.6
17.1
1.45
1.37
inr
0.38
46
279
53
220
2.86
9.22
2.3
1.7
—
—
—
0
0
121
746
2.39
9.12
3.0
2.2
80.03
77.32
nmol/l
0.50
105
640
124
794
2.29
8.29
6.9
4.1
39.25
47.62
ng/l
0.34
106
592
135
896
2.32
8.28
6.9
4.2
0.00
0.00
estimate
-0.00
36
194
145
996
2.35
8.15
7.6
5.9
10.48
11.49
umol/l
0.61
138
937
28
86
3.59
7.97
1.7
1.8
1.67
1.66
g/l
0.01
22
74
99
589
2.24
7.77
2.8
2.1
169.20
222.66
u/l
0.38
94
553
89
511
2.25
7.58
1.9
1.6
20.22
21.39
nmol/l
0.28
72
421
132
898
2.18
7.23
8.8
5.5
0.00
0.00
estimate
-0.00
36
177
104
649
2.15
7.08
4.4
3.4
2.36
2.35
mmol/l
0.08
90
564
110
709
2.11
6.80
5.5
3.3
—
—
—
0
0
75
420
2.19
6.64
3.0
2.2
—
—
—
0
0
131
909
2.10
6.57
7.1
4.1
0.00
0.00
estimate
-0.00
35
175
179
1408
2.49
6.51
13.0
7.3
83.20
80.70
u/l
0.26
172
1310
38
161
2.65
6.23
12.6
6.4
10.88
10.10
mmol/l
0.28
38
152
120
818
2.03
6.18
2.4
2.0
101.67
94.16
pmol/l
0.70
61
408
90
556
2.05
6.07
4.9
3.2
0.33
0.42
e6/l
0.29
74
432
17
46
3.92
5.77
1.7
1.5
—
—
—
0
0
17
46
3.92
5.77
1.7
1.5
—
—
—
0
0
11
13
8.84
5.63
1.2
1.1
—
—
—
0
0
19
58
3.49
5.44
4.3
2.2
1.59
1.71
mg/l
0.28
19
51
16
34
4.99
5.42
1.4
1.2
—
—
—
0
0
100
662
1.94
5.39
4.6
3.4
1838.42
1586.08
ng/l
0.24
87
571
18
55
3.48
5.15
1.6
2.7
—
—
—
0
0
67
392
2.02
5.11
1.9
1.7
1.33
1.30
mg/l
0.05
56
305
42
205
2.30
5.07
4.7
3.7
—
—
—
0
0
138
1031
1.92
5.02
3.9
3.1
63.20
51.58
u/l
0.57
127
950
15
33
4.80
4.97
1.7
1.4
—
—
—
0
0
79
494
1.94
4.96
8.6
4.5
0.00
0.00
estimate
-0.00
36
174
70
422
1.97
4.88
2.2
1.7
1455.69
1219.15
nmol/l
0.92
51
320
37
176
2.33
4.72
6.4
3.4
1.81
2.19
mmol/l
0.33
31
141
12
23
5.45
4.52
1.4
1.5
—
—
—
0
0
19
66
3.06
4.46
1.8
2.1
39.78
39.96
u/l
0.01
19
59
12
24
5.23
4.38
1.6
1.5
—
—
—
0
0
7
6
11.99
4.30
1.3
1.3
273.03
140.83
iu/ml
—
7
6
90
609
1.81
4.30
2.9
2.3
59.80
65.02
u/l
0.25
85
564
114
829
1.78
4.26
3.3
2.6
—
—
—
0
0
36
177
2.24
4.25
6.6
3.4
5.85
5.82
kpa
0.08
36
169
17
57
3.15
4.22
2.3
1.6
—
—
—
0
0
52
296
1.99
4.21
2.5
1.8
30.35
30.15
s
0.06
52
287
13
30
4.54
4.20
1.5
1.6
—
—
—
0
0
12
26
4.82
4.12
1.6
1.5
—
—
—
0
0
198
1732
2.49
4.04
35.8
16.0
28.14
24.64
mg/l
0.87
188
1419
86
584
1.78
4.00
4.4
3.8
21.54
9.06
mg/mmol
0.73
53
365
63
389
1.87
3.99
3.6
3.1
2.49
2.47
mmol/l
1.03
55
337
115
849
1.75
3.99
3.4
2.4
—
—
—
0
0
189
1627
2.18
3.93
29.0
15.6
69.82
74.26
ml/min/173m2
1.62
167
1354
8
11
7.50
3.89
1.5
1.5
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
17
60
2.99
3.89
2.1
2.2
0.45
0.38
u/ml
—
8
36
29
135
2.32
3.88
2.5
1.6
—
—
—
0
0
31
150
2.24
3.80
4.9
2.8
4.38
4.16
kpa
0.25
31
142
7
8
8.99
3.80
1.6
1.4
—
—
—
0
0
7
8
8.99
3.80
1.6
1.4
—
—
—
0
0
15
51
3.08
3.65
1.7
1.5
—
—
—
0
0
9
18
5.17
3.41
6.7
3.5
—
—
—
0
0
16
59
2.85
3.40
1.4
1.2
—
—
—
0
0
43
246
1.93
3.40
5.8
4.9
32.00
32.28
%
0.05
31
157
13
38
3.57
3.37
3.5
2.5
15.23
15.59
%
—
6
16
10
23
4.50
3.35
1.9
1.3
—
—
—
0
0
11
28
4.08
3.34
1.8
1.9
33.64
32.43
pg
0.51
11
28
23
104
2.35
3.29
4.7
2.9
1.10
1.41
mmol/l
0.17
18
77
11
30
3.80
3.13
1.2
1.6
—
—
—
0
0
11
30
3.80
3.13
1.2
1.6
—
—
—
0
0
11
31
3.68
3.03
1.9
1.3
—
—
—
0
0
17
70
2.55
2.96
2.1
1.8
—
—
—
0
0
64
432
1.68
2.90
2.0
1.8
453.79
455.60
pmol/l
0.02
47
353
11
33
3.45
2.85
4.3
3.2
65.64
58.52
%
0.78
11
33
9
23
4.03
2.80
1.2
1.4
—
—
—
0
0
9
23
4.03
2.80
1.2
1.4
—
—
—
0
0
36
207
1.88
2.80
3.1
2.4
7.21
8.41
umol/l
0.16
29
178
52
337
1.71
2.72
4.3
2.8
2.18
1.06
e6/l
0.55
31
204
17
74
2.41
2.65
2.5
1.9
—
—
—
0
0
7
16
4.48
2.49
2.3
1.3
—
—
—
0
0
6
12
5.11
2.42
1.0
1.2
—
—
—
0
0
5
8
6.36
2.38
1.8
2.6
—
—
—
0
0
12
47
2.64
2.31
1.4
1.3
—
—
—
0
0
91
700
1.51
2.30
8.6
4.5
—
—
—
0
0
37
229
1.74
2.27
6.6
5.7
0.81
1.28
mmol/l
0.28
28
189
7
18
3.98
2.27
1.1
1.4
—
—
—
0
0
5
9
5.65
2.22
1.2
2.1
—
—
—
0
0
5
9
5.65
2.22
1.2
2.1
—
—
—
0
0
7
19
3.77
2.17
1.1
1.4
—
—
—
0
0
29
171
1.80
2.09
2.9
2.4
32.21
28.87
u/l
0.20
24
139
5
10
5.09
2.08
1.0
1.0
—
—
—
0
0
197
1813
1.86
2.06
19.1
10.9
24.46
24.63
u/l
0.04
190
1735
19
98
2.03
2.02
5.0
2.5
1.07
1.23
%
0.33
19
98
47
320
1.60
2.02
4.6
3.0
2.43
2.14
e6/l
0.11
27
191
32
197
1.73
2.01
3.2
2.7
4.45
8.07
ug/l
0.87
27
167
50
347
1.57
1.98
1.2
1.2
0.68
1.21
u/ml
1.41
13
100
7
21
3.41
1.98
1.4
1.3
—
—
—
0
0
7
21
3.41
1.98
1.4
1.3
—
—
—
0
0
5
11
4.62
1.95
1.4
1.5
—
—
—
0
0
6
16
3.82
1.95
2.0
1.8
—
—
—
0
0
149
1296
1.47
1.88
4.6
4.1
15.69
15.06
pmol/l
1.84
131
1139
18
94
2.00
1.86
5.2
2.5
0.54
0.68
%
1.36
18
94
177
1597
1.56
1.84
5.8
4.9
2.01
2.05
mu/l
0.12
163
1419
7
23
3.11
1.81
2.0
4.1
—
—
—
0
0
201
1876
1.87
1.79
48.1
23.6
4.25
4.42
e12/l
4.50
195
1815
201
1876
1.87
1.79
48.3
23.5
38.90
39.75
%
1.85
194
1753
180
1636
1.56
1.75
8.5
6.5
41.95
40.69
mmol/mol
0.82
164
1508
5
13
3.91
1.72
8.4
2.2
—
—
—
0
0
10
40
2.57
1.69
2.1
1.5
—
—
—
0
0
10
40
2.57
1.69
2.1
1.5
—
—
—
0
0
24
144
1.75
1.66
3.8
3.1
54.36
61.21
ml/min/173m2
0.32
11
66
10
42
2.45
1.64
1.4
1.5
—
—
—
0
0
7
26
2.75
1.59
1.0
1.4
—
—
—
0
0
5
15
3.39
1.53
1.4
1.7
—
—
—
0
0
5
15
3.39
1.53
1.4
1.7
—
—
—
0
0
5
15
3.39
1.53
1.4
1.7
—
—
—
0
0
13
65
2.06
1.52
5.4
3.0
24.45
24.81
mmol/l
0.21
13
60
35
238
1.56
1.52
11.5
8.4
—
—
—
0
0
6
21
2.91
1.51
1.3
1.3
—
—
—
0
0
6
21
2.91
1.51
1.5
1.3
—
—
—
0
0
6
21
2.91
1.51
1.5
1.3
—
—
—
0
0
5
16
3.17
1.44
2.2
4.4
—
—
—
0
0
6
22
2.77
1.44
1.5
1.3
—
—
—
0
0
11
53
2.13
1.41
3.6
2.3
22.95
24.27
mmol/l
0.59
11
53
6
23
2.65
1.37
1.0
1.1
—
—
—
0
0
6
24
2.54
1.31
1.3
1.5
—
—
—
0
0
5
18
2.82
1.29
1.2
1.3
—
—
—
0
0
5
18
2.82
1.29
1.2
1.3
—
—
—
0
0
5
18
2.82
1.29
1.2
1.3
—
—
—
0
0
5
18
2.82
1.29
1.2
1.3
—
—
—
0
0
5
18
2.82
1.29
1.2
1.3
—
—
—
0
0
5
19
2.67
1.22
1.0
1.8
—
—
—
0
0
8
38
2.15
1.19
1.6
1.3
—
—
—
0
0
7
30
2.38
1.13
1.3
1.4
—
—
—
0
0
10
52
1.97
1.08
1.6
1.5
275.80
260.18
ug/g
—
5
28
7
33
2.16
1.06
1.0
1.1
—
—
—
0
0
5
22
2.30
1.04
1.0
1.1
—
—
—
0
0
7
35
2.03
1.01
1.1
1.1
—
—
—
0
0
7
35
2.03
1.01
1.3
1.2
14.71
14.54
u/l
—
7
28
6
27
2.26
0.94
1.3
1.1
—
—
—
0
0
6
28
2.17
0.92
2.0
1.9
—
—
—
0
0
182
1722
1.34
0.84
5.9
5.4
2.50
2.61
mmol/l
0.84
160
1550
178
1687
1.29
0.75
6.2
5.1
6.17
6.10
mmol/l
0.26
159
1519
5
25
2.02
0.73
1.4
1.6
—
—
—
0
0
7
41
1.73
0.70
2.4
1.7
—
—
—
0
0
5
93
0.53
0.68
3.6
1.7
—
—
—
0
0
5
28
1.80
0.66
1.4
1.1
—
—
—
0
0
176
1675
1.26
0.65
5.6
4.8
4.34
4.51
mmol/l
1.42
156
1518
11
73
1.53
0.57
1.7
1.6
—
—
—
0
0
174
1662
1.23
0.56
5.7
4.8
1.41
1.46
mmol/l
0.78
155
1492
75
668
1.19
0.54
7.2
5.3
3.28
2.79
ug/l
0.12
66
590
10
67
1.52
0.50
1.6
1.5
—
—
—
0
0
43
495
0.84
0.45
1.6
1.6
1.45
1.32
mmol/l
0.33
34
398
166
1600
1.15
0.37
5.2
4.3
1.38
1.28
mmol/l
0.96
146
1428
8
63
1.28
0.28
1.4
1.1
—
—
—
0
0
8
63
1.28
0.28
1.4
1.1
—
—
—
0
0
23
197
1.19
0.27
1.3
1.4
—
—
—
0
0
9
77
1.18
0.24
1.3
1.2
—
—
—
0
0
10
125
0.79
0.23
3.9
2.0
9.59
13.03
nmol/l
—
10
113
57
529
1.10
0.23
4.0
4.7
19.32
20.73
%
0.39
28
259
42
383
1.12
0.23
3.9
3.1
0.61
0.85
ug/l
1.51
30
261
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
5
46
1.09
0.09
1.8
1.5
—
—
—
0
0
20
203
0.98
0.00
1.6
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
6.9
—
233.63
—
0
8
0
7
0.00
-0.00
0.0
2.3
—
13.81
—
0
7
0
8
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
38.58
—
0
8
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
7.74
—
0
6
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.7
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CHRYSTAL_NOS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CHRYSTAL_NOS | 1.612 [1.3, 2.0] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.049 |
During the follow-up period (1.1.1998 — 31.12.2019), 301 out of 641 females with CHRYSTAL_NOS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CHRYSTAL_NOS | 1.755 [1.31, 2.36] | < 0.001 |
| Birth year | 0.982 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 218 out of 482 males with CHRYSTAL_NOS died.
Mortality risk
Mortality risk for people of age
years, who have CHRYSTAL_NOS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.143% | 0.325% |
| 5 | 0.84% | 1.923% |
| 10 | 2.169% | 4.736% |
| 15 | 4.007% | 8.626% |
| 20 | 7.146% | 14.061% |
Relationships between endpoints
↥Index endpoint: CHRYSTAL_NOS – Other/unspecified crystal arthropathies
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data